Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 30, 2011

Astellas Sells Prosidion Subsidiary’s DPP-IV Inhibitor Diabetes Assets to Royalty Pharma for $609M

  • Astellas’ biotech subsidiary Prosidion has sold its dipeptidase IV (DPP-IV) inhibitor patent estate for type 2 diabetes therapy, and the associated royalty stream, to asset acquisition firm Royalty Pharma for $609 million in cash. Prosidion was acquired by Astellas as part of the latter’s buy-out of OSI Pharmaceuticals a year ago.

    Under terms of the deal Royalty will receive 100% of royalty payments and milestones relating to the DPP-IV assets and existing licensing deals, and will take over from Prosidion the relevant patent estate and its management.  Prosidion acquired a portfolio of medical-use patents relating to the use of  DPP-IV inhibitors in the treatment of type 2 diabetes back in 2004, and has since nonexclusively outlicensed the IP to pharmaceutical companies worldwide.

    Oxford, U.K.-based Prosidion is dedicated to the discovery and development of novel therapies for type 2 diabetes and obesity. Its lead compound PSN821 is an orally administered G protein-coupled receptor GPR119 agonist currently in Phase II development for the treatment of type 2 diabetes. A second candidate, PSN842, has completed preclinical development as a potential treatment for obesity.

    Astellas says it is also looking at potential options for Prosidion’s non-DPP-IV assets, including its pipeline and R&D capabilities. Possibilities, including a merger or sale of some or all of the assets, or minority investments and strategic alliances, are all being evaluated.

    Royalty Pharma invests in revenue-producing intellectual property, and primarily royalty interests in marketed and late-stage development biopharmaceuticals. The firm says it currently owns royalty interests in 17 approved and marketed biopharmaceutical products, and another 5 products undergoing clinical trials and/or regulatory review in the U.S. and Europe.

    In April Royalty paid $487 million to acquire the rights to certain royalties payable on sales of the pharmacological stress agent Lexiscan® (regadenoson) and the injectable antibiotic Cubicin® (daptomycin) from an undisclosed seller.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »